Leiner Naproxen Sales Decline Due To Recent Heart Risk Concerns
This article was originally published in The Tan Sheet
Executive Summary
Study data associating naproxen with a higher cardiac risk translated into a 30% decline in Leiner's fiscal third-quarter sales of the private label analgesic
You may also be interested in...
Vitamin Of Champions: Leiner Inks Deal With General Mills
Leiner will supply General Mills with vitamins for the launch of two new product lines under a distribution deal signed during the firm's fiscal second quarter
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands